Immusoft

📍 Seattle, United States🗓 Founded 2009👥 22 employees💰 Last funded Jan 2022
Biotechnology Research🌐 immusoft.com
Website LinkedIn
Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.
3
Total investors
0
Early stage
0
Mid stage
2
Late stage
2009
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
China
1
Investor activity2018–2022 · investors recorded per year
2018220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Immusoft?
Immusoft has 3 investors on record on gritt.io and 2 late-stage investors.
When did Immusoft last raise funding?
The most recent investment in Immusoft recorded on gritt.io was in January 2022.
When was Immusoft founded?
Immusoft was founded in 2009.
What industry is Immusoft in?
Immusoft operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Immusoft based?
Immusoft is headquartered in Seattle, United States.